From the 1Division of Cancer Epidemiology and Genetics and 3Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland; 2Gynecology and Colposcopy Clinic Student Health Service, University of California, Santa Barbara, California; 4Departments of Molecular Genetics and Microbiology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, School of Medicine, Albuquerque, New Mexico; and 5Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland.
Supported by the National Cancer Institute, National Institutes of Health Department of Health and Human Services contracts CN-55153, CN-55154, CN-55155, CN-55156, CN-55157, CN-55158, CN-55159 and CN-55105. Also supported in part by intramural research program of the National Cancer Institute. Some of the equipment and supplies used in these studies were donated or provided at reduced cost by Digene Corporation, Gaithersburg, MD; Cytyc Corporation, Marlborough, MA; National Testing Laboratories, Fenton, MO; DenVu, Tucson, AZ; TriPath Imaging, Inc., Burlington, NC; and Roche Molecular Systems Inc., Alameda, CA.
The authors thank the ALTS Group Investigators for their help in planning and conducting the trial and Information Management Services, Inc., Rockville, Maryland, for data management and programming support.
Presented in part at the 24th International Papillomavirus Conference, Beijing, China, November 3–9, 2007.
Corresponding author: Philip E. Castle, PhD, MPH, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard. Room 5004, EPS MSC 7234, Bethesda, MD 20892-7234; e-mail: [email protected].
Financial Disclosure Dr. Cox received honoraria from and was a consultant to Digene Corporation (Gaithersburg, MD). Dr. Gravitt is a consultant for and has received research funding from Roche Molecular Diagnostics (Pleasanton, CA), who manufactured the HPV Linear Array test used in this study. The other authors have no potential conflicts of interest to disclose.)
